• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Report of a clinical trial of a Canadian preparation of antihemophilic factor.加拿大抗血友病因子制剂的一项临床试验报告。
Can Med Assoc J. 1979 Aug 18;121(4):422-4, 427.
2
[Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies].
Schweiz Med Wochenschr. 1991 Nov 2;121(44):1624-7.
3
Lyophilized cryoprecipitate for children with hemophilia A.
J Med Assoc Thai. 2002 Jun;85 Suppl 1:S293-7.
4
[Clinical evaluation of a new factor VIII concentrate in hemophilic children].
Pediatr Med Chir. 1983 May-Jun;5(3):49-55.
5
Factor VIII concentrate for hemophilia: comparison of two heat-treated products.用于血友病的凝血因子 VIII 浓缩剂：两种热处理产品的比较。
CMAJ. 1987 Jan 15;136(2):150-2.
6
Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.经典血友病患者对抗血友病因子浓缩物输注反应的研究。通过促凝血和免疫技术测定的抗血友病因子半衰期的差异。
J Clin Invest. 1972 Oct;51(10):2593-6. doi: 10.1172/JCI107076.
7
A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.一种用于估计甲型血友病患者凝血因子 VIII 个体药代动力学参数的有限采样策略。
Ther Drug Monit. 2007 Feb;29(1):20-6. doi: 10.1097/FTD.0b013e3180311384.
8
[The dosage of antihemophilic globulin, or antihemophilic plasma as well as Cohn's fraction I in factor VIII deficiency].
Folia Haematol Int Mag Klin Morphol Blutforsch. 1970;93(3):363-8.
9
Measurement of antihemophilic factor activity in plasma.
J Lab Clin Med. 1966 Jun;67(6):1025-35.
10
In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.体内因子VIII和因子IX的恢复：临床环境中的个体内和个体间差异
Haemophilia. 2007 Jan;13(1):2-8. doi: 10.1111/j.1365-2516.2006.01401.x.

本文引用的文献

1
Acquired circulating anticoagulants in hemophilia A.
N Engl J Med. 1969 Oct 16;281(16):866-73. doi: 10.1056/NEJM196910162811603.
2
Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates.生产临床有效中高纯度凝血因子VIII浓缩物的方法。
Br J Haematol. 1971 Jul;21(1):1-20. doi: 10.1111/j.1365-2141.1971.tb03413.x.
3
Clinical investigation of intermediate- and high-purity antihaemophilic factor (factor VIII) concentrates.
Br J Haematol. 1971 Jul;21(1):21-41. doi: 10.1111/j.1365-2141.1971.tb03414.x.
4
Development of large-scale fractionation methods. 3. Preparation of a factor VIII concentrate of intermediate-purity.
Vox Sang. 1972;23(5):402-12. doi: 10.1111/j.1423-0410.1972.tb03827.x.
5
Adverse reactions to factor VIII infusions.
Ann Intern Med. 1977 Aug;87(2):248. doi: 10.7326/0003-4819-87-2-248_1.
6
Current therapy for hemophiliacs: home care and therapeutic complications.
Mt Sinai J Med. 1977 May-Jun;44(3):316-31.

加拿大抗血友病因子制剂的一项临床试验报告。

Report of a clinical trial of a Canadian preparation of antihemophilic factor.

作者信息

Magnin A A, Johnson S E

出版信息

Can Med Assoc J. 1979 Aug 18;121(4):422-4, 427.

PMID:466616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1704378/
Abstract

A clinical trial of a Canadian preparation of antihemophilic factor has been completed. The mean percentage increase in the factor VIII coagulant activity in the plasma was determined to be 2.1 +/- 0.8 per unit per kilogram dose, which compares very favourably with published data. The mean half-life of antihemophilic factor was found to be 14.7 hours. Side effects and reactions to the product were minimal and the product has been rated as clinically effective. No significant differences between lots were noted in the in vivo response or the half-life.

摘要

一项关于加拿大制备的抗血友病因子的临床试验已经完成。血浆中因子VIII凝血活性的平均百分比增加量经测定为每千克剂量每单位2.1±0.8，与已发表的数据相比非常有利。抗血友病因子的平均半衰期为14.7小时。该产品的副作用和反应极小，且已被评定为临床有效。各批次之间在体内反应或半衰期方面未发现显著差异。